Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia. - Wikidata - wikimedia - TriplyDB

Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia.

Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia.

http://www.wikidata.org/entity/Q37396170

about

Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.

P2860

Q38604382-253141BC-F542-4BE8-81F9-D6186CFD0CDB

P2860

Impact of the TCF7L2 genotype on risk of hypoglycaemia and glucagon secretion during hypoglycaemia.

http://www.wikidata.org/entity/Q37396170

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Impact of the TCF7L2 genotype ...... ecretion during hypoglycaemia.

@en

Impact of the TCF7L2 genotype ...... ecretion during hypoglycaemia.

@nl

type

label

Impact of the TCF7L2 genotype ...... ecretion during hypoglycaemia.

@en

Impact of the TCF7L2 genotype ...... ecretion during hypoglycaemia.

@nl

prefLabel

Impact of the TCF7L2 genotype ...... ecretion during hypoglycaemia.

@en

Impact of the TCF7L2 genotype ...... ecretion during hypoglycaemia.

@nl

P1433

Q37396170-63413B94-A4B7-4A9E-8412-8085A62C5EC2

P1476

Q37396170-EA2CB8F6-2BD9-4CAE-806E-DD037CAD5451

P2093

Q37396170-427F0501-F01B-4C2A-B496-FEA22E962BD7

Q37396170-88090A63-A612-4967-A4C6-B4D8E3AD46A2

Q37396170-9EFEB0FE-4AE5-4112-8FB1-404AE403492E

Q37396170-C1318C60-71FB-420A-98B9-CC46376353F0

Q37396170-C75AEFCC-32B6-44B7-8616-07C2F8AFB17B

P2860

Q37396170-0C7F3A9B-3FB6-45B4-BFAD-9967E8435305

Q37396170-1314C3E2-D534-4647-B690-73D7A54BCAAE

Q37396170-24CC6475-9260-4F7E-9173-179BCD1059A5

Q37396170-2A5E933C-AE24-4B8C-8EA9-ED7EF2D35CE9

Q37396170-30657FE3-EBC5-438F-9FB6-AC36F55B29C3

Q37396170-320DFE1F-4B7F-4BC4-BD6F-9AF165725B37

Q37396170-3456A24A-B3B8-443D-9F73-1814AA9688DA

Q37396170-36228340-D234-4136-B007-466CF068F0AB

Q37396170-4166C309-8A63-4782-BD20-6B4AC5A0BA38

Q37396170-4AD28DB3-D4B1-4F61-B9EA-07A2533DD03E

P304

Q37396170-67620A5C-B70B-4381-BFE7-7734857EE309

P31

Q37396170-7EBBA57A-4A03-4F1D-8049-0F47C6E371DC

P356

Q37396170-6BE72A46-153C-44E2-AF2A-1732DF5472A5

P433

Q37396170-54177C92-41F9-49D6-9403-602D5D953B31

P478

Q37396170-9061F523-74D0-4C5F-8EBB-5E5417D74E5D

P50

Q37396170-5346D5D2-5143-4C71-B208-8A55D175F56A

Q37396170-8463C2D2-93B6-4C9D-BCE1-810D5E9E347A

Q37396170-C007BAF6-B989-4FBC-A34E-7D1B2D1C2CE0

Q37396170-CB78C7F8-C953-41B5-A20A-BA9C44DA5803

Q37396170-E681093C-FD8F-4F83-95D9-38F5A90E4E8D

P577

Q37396170-1341797A-7B43-4CDF-9916-586B520216EB

P698

Q37396170-A61C2D60-B56C-4FFD-9352-87AE6CAB7180

P921

Q37396170-DF1E04DF-5F58-4CBE-8F2D-FDF040AE5D94

P932

Q37396170-23EE9F23-8994-433A-A82D-D534A3AD90E3

P356

P1433

Endocrine connections

P1476

Impact of the TCF7L2 genotype ...... ecretion during hypoglycaemia.

@en

P2093

Allan A Vaag

http://www.w3.org/2001/XMLSchema#string

Birger Thorsteinsson

http://www.w3.org/2001/XMLSchema#string

Lise Grimmeshave

http://www.w3.org/2001/XMLSchema#string

Rikke Due-Andersen

http://www.w3.org/2001/XMLSchema#string

Thomas Høi-Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms.

The T-allele of TCF7L2 rs7903146 associates with a reduced compensation of insulin secretion for insulin resistance induced by 9 days of bed rest.

Self-reported non-severe hypoglycaemic events in Europe.

Influence of erythropoietin on cognitive performance during experimental hypoglycemia in patients with type 1 diabetes mellitus: a randomized cross-over trial

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes.

The effect of antecedent hypoglycaemia on β₂-adrenergic sensitivity in healthy participants with the Arg16Gly polymorphism of the β₂-adrenergic receptor.

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

The Arg16Gly variant of the beta2-adrenergic receptor predisposes to hypoglycemia unawareness in type 1 diabetes mellitus.

Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know.

Effects of TCF7L2 polymorphisms on obesity in European populations.

P304

53-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1530/EC-16-0050

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Jens Juul Holst

Valeriya Lyssenko

Ulrik Pedersen-Bjergaard

Peter Lommer Kristensen

P577

2016-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27758844

http://www.w3.org/2001/XMLSchema#string

P921

P932

5097143

http://www.w3.org/2001/XMLSchema#string